Recently added

Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab

Yang, S. Y. Cindy; Han, Ming; Liu, Zhihui Amy; Berman, A Hal K.; Lo Giacco, Deborah; Berche, Roger; Hernando-Calvo, Alberto; Vila-Casadesús, Maria; Matito, Judit; Saavedra, Omar; GARRALDA, Elena; Vivancos, Ana (American Society of Clinical Oncology, 2024-08-23)

Circulating cell-free and extracellular vesicles-derived microRNA as prognostic biomarkers in patients with early-stage NSCLC: results from RESTING study

Petracci, Elisabetta; Pasini, Luigi; Urbini, Milena; stella, franco; Davoli, Fabio; FELIP, ENRIQUETA (BMC, 2024-08-22)

MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer

Capitán-Leo, Daniel; Casacuberta-Serra, Sílvia; González-Larreategui, Íñigo; Soucek, Laura (Springer Nature, 2024-08-21)

Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer

Bernardez, Beatriz; Bruna, Jordi; Arriola, Edurne; De Castro, Javier; Garcia Campelo, Rosario; Bernabé, Reyes; FELIP, ENRIQUETA (Adis, 2024-08)

SEOM-GEICO Clinical Guidelines on cervical cancer (2023)

Ramchandani-Vaswani, Avinash; Romero, Ignacio; sanchez lorenzo, luisa; Bermejo-Pérez, María José; Estévez-García, Purificación; Luis, Manso; Fariñas-Madrid, Lorena (Springer, 2024-11)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Vall d'Hebron Institut d'Oncologia - VHIO: Recent submissions

Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab

Circulating cell-free and extracellular vesicles-derived microRNA as prognostic biomarkers in patients with early-stage NSCLC: results from RESTING study

MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer

Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer

SEOM-GEICO Clinical Guidelines on cervical cancer (2023)

Scientia. Dipòsit d'Informació Digital del Departament de Salut

Vall d'Hebron Institut d'Oncologia - VHIO: Recent submissions

Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab ﻿

Circulating cell-free and extracellular vesicles-derived microRNA as prognostic biomarkers in patients with early-stage NSCLC: results from RESTING study ﻿

MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer ﻿

Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer ﻿

SEOM-GEICO Clinical Guidelines on cervical cancer (2023) ﻿

Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors Treated With Pembrolizumab

Circulating cell-free and extracellular vesicles-derived microRNA as prognostic biomarkers in patients with early-stage NSCLC: results from RESTING study

MYC and KRAS cooperation: from historical challenges to therapeutic opportunities in cancer

Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung Cancer

SEOM-GEICO Clinical Guidelines on cervical cancer (2023)